Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Study Information
Alliance Study ID: AFT-32
NCT Study ID (ClinicalTrials.gov): NCT03478514
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Kami Maddocks, MD
Status: ACTIVE_NOT_RECRUITING
Study Description
The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary objective of the study being to assess median PFS and the secondary objectives to include ORR, CR, DOR, OS and toxicity. Subjects will be enrolled and treated with palbociclib and ibrutinib with each cycle of therapy being 28 days. Treatment will be based on the recommended phase II dose (RP2D) from the phase I combination trial.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Locations (9)
City of Hope National Medical Center
Duarte, California 91010
United States
University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland 21201
United States
Massachusetts General Hospital
Boston, Massachusetts 02114
United States
St. Joseph Mercy Hospital Cancer Care Center
Ypsilanti, Michigan 48197
United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York 14263
United States
Weill Cornell Medical College
New York, New York 10065
United States
University of North Carolina
Chapel Hill, North Carolina 27599
United States
Ohio State University
Columbus, Ohio 43210
United States
Medical University of South Carolina – Hollings Cancer Center
Charleston, South Carolina 29425
United States
Data Sources & Contacts
Full trial details
For more Information